论文部分内容阅读
目的探讨舒血宁联合甲钴胺在面神经炎患者中的临床治疗效果及对预后的影响。方法取2016年2月至2017年4月医院收治的面神经炎患者80例,随机数字法分为对照组(n=40)和观察组(n=40)。对照组采用地塞米松针、甲钴胺等常规治疗,观察组联合舒血宁治疗,比较2组临床疗效及对预后的影响。结果 2组治疗前改良Portmann简易评分比较差异无统计学意义(P>0.05);观察组治疗后1周、2周、3周及4周改良Portmann简易评分,均高于对照组(P<0.05);观察组治疗后4周不良反应发生率为7.50%与对照组5.00%比较差异无统计学意义(P>0.05)。结论面神经炎患者在甲钴胺基础上联合舒血宁治疗效果理想,能改善患者预后,值得推广应用。
Objective To investigate the clinical effect of Shuxuening combined with mecobalamin in patients with facial neuritis and its prognosis. Methods Eighty patients with facial neuritis treated in our hospital from February 2016 to April 2017 were randomly divided into control group (n = 40) and observation group (n = 40). The control group was treated with routine dexamethasone and methylcobalamin, and the observation group was treated with Shuxuening. The clinical effects and prognosis of the two groups were compared. Results There was no significant difference between the two groups before treatment (P> 0.05). The Portmann simple scores at 1 week, 2 weeks, 3 weeks and 4 weeks after treatment in the observation group were significantly higher than those in the control group (P <0.05) ). There was no significant difference between the observation group and the control group in the incidence of adverse reactions after 4 weeks of treatment (7.50% vs 5.00%, P> 0.05). Conclusion The patients with facial neuritis are effective on the basis of mecobalamin combined with Shuxuening, which can improve the prognosis of patients. It is worth popularizing and applying.